What's Going On With Mirati Therapeutics Stock?

Mirati Therapeutics, Inc. MRTX shares are trading higher Friday. Several analysts updated their price targets on the stock, and investors consider reports of a potential acquisition of the company. 

What To Know:

Several analysts updated Mirati price targets on Friday:

• BMO Capital analyst Evan David Seigerman maintained Mirati Therapeutics with a Market Perform rating and raised the price target from $31 to $72.
• JMP Securities analyst Silvan Tuerkcan maintained Mirati Therapeutics with a Market Outperform and raised the price target from $58 to $82.

Investors may also be considering reports of a potential Sanofi SNY acquisition of Mirati Therapeutics that surfaced on Thursday. 

Shares of MRTX are trading on heavy volume Friday. According to data from Benzinga Pro, more than 1.53 million shares have been traded in the session, already exceeding the stock's 100-day average of 1.469 million shares.

Related News: What's Going On With T2 Biosystems Stock? 

MRTX Price Action: According to Benzinga Pro, Mirati Therapeutics shares are  0.2% at $62.51 at the time of publication.

Image: Clker-Free-Vector-Images from Pixabay